SunBio선바이오
067370 · KOSDAQ · ₩067370 · 선바이오
₩5,680▲ ₩60 (1.07%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | ₩14B | ₩8.7B | ₩12B | ₩7.4B |
| Cost of sales | ₩5.3B | ₩2.8B | ₩3.7B | ₩2.9B |
| Gross profit | ₩8.3B | ₩5.9B | ₩8.6B | ₩4.5B |
| Operating income | ₩5B | −₩533M | ₩5.2B | ₩191M |
| Net income | ₩2.8B | −₩104M | ₩4.6B | ₩869M |
| Net income to shareholders | ₩2.8B | −₩104M | ₩4.6B | ₩869M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total assets | ₩61B | ₩61B | ₩48B | ₩43B |
| Current assets | ₩11B | ₩13B | ₩12B | ₩16B |
| Cash and equivalents | ₩2.8B | ₩6.2B | ₩5.8B | ₩1.1B |
| Total liabilities | ₩32B | ₩34B | ₩20B | ₩19B |
| Current liabilities | ₩21B | ₩17B | ₩19B | ₩18B |
| Borrowings | ₩18B | ₩14B | ₩16B | ₩17B |
| Total equity | ₩29B | ₩27B | ₩28B | ₩24B |
| Shareholders' equity | ₩29B | ₩27B | ₩28B | ₩24B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Cash from operations | ₩3.8B | ₩1.2B | ₩5B | ₩1.6B |
| Capital spending | ₩3.2B | ₩16B | ₩8.6B | ₩19B |
| Free cash flow | ₩577M | −₩15B | −₩3.6B | −₩17B |
| Dividends paid | ₩0 | ₩923M | ₩615M | — |
Consolidated where available. Amounts in won.
Also known as: SunBio / 선바이오 / 067370 / KRX:067370
Source: KRX statistical information